Business
Cigna Enables Coverage for RhinAer®
MOUNTAIN VIEW, Calif., June 27, 2025--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna’s list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients
About this update from The Cigna Group
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/ab80c33c9c2a55500a02979fcc6b1bdc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HNsqr7V3S4NZXIhZem2hrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ab80c33c9c2a55500a02979fcc6b1bdc","width":480,"height":240}},"lazy":false},{"type":"text","content":"Policy Update Validates Clinical Value and Expands Patient Access to Innovative Chronic Rhinitis Treatment","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., June 27, 2025--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna’s list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis.","length":577,"tagName":"p"},{"type":"text","content":"Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna’s policy update highlights the growing recognition of RhinAer’s clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management.","length":473,"tagName":"p"},{"type":"text","content":""Cigna’s decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients," said Matt Brokaw, CEO of Aerin Medical. "Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, a...